Scholarlink

<p>Remibrutinib (Rhapsido<sup>®</sup>), is an innovative oral Bruton’s tyrosine kinase (BTK) inhibitor discovered and developed by Novartis for the treatment of chronic spontaneous urticaria (CSU), an autoimmune disease. It is a covalent, irreversible inhibitor that targets BTK, a key signalling node in the FcεRI pathway of mast cells and basophils, thereby suppressing the release of histamine and other inflammatory mediators. In September 2025, remibrutinib received its first US FDA approval for the treatment of CSU for adult patients who remain symptomatic despite H1 antihistamine treatment. This approval marks a significant advancement in CSU care that targets mast cell and basophil activation, two key contributors involved in hive formation and itching. This article reviews the development journey, scientific rationale, chemistry, pharmacological properties (pharmacokinetic, pharmacodynamics and safety profile), clinical trials, and granted patents that led to first FDA approval of an oral treatment for adult patients with CSU.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemistry, pharmacology and spotlight on the clinical trials of remibrutinib: a first in class, oral Bruton’s tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria

  • 期刊论文

  • 发表日期：

    2026年5月5日

查看全文
  • Shah Alam Khan,
  • Abdul Qadir,
  • Aqsa Khan,
  • Simran Kour,
  • Asif Husain

摘要

Remibrutinib (Rhapsido®), is an innovative oral Bruton’s tyrosine kinase (BTK) inhibitor discovered and developed by Novartis for the treatment of chronic spontaneous urticaria (CSU), an autoimmune disease. It is a covalent, irreversible inhibitor that targets BTK, a key signalling node in the FcεRI pathway of mast cells and basophils, thereby suppressing the release of histamine and other inflammatory mediators. In September 2025, remibrutinib received its first US FDA approval for the treatment of CSU for adult patients who remain symptomatic despite H1 antihistamine treatment. This approval marks a significant advancement in CSU care that targets mast cell and basophil activation, two key contributors involved in hive formation and itching. This article reviews the development journey, scientific rationale, chemistry, pharmacological properties (pharmacokinetic, pharmacodynamics and safety profile), clinical trials, and granted patents that led to first FDA approval of an oral treatment for adult patients with CSU.